Jeffrey Statland
Jeffrey Statland
University of Kansas Medical Center
Verified email at - Homepage
Cited by
Cited by
Genome-wide analyses identify KIF5A as a novel ALS gene
A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ...
Neuron 97 (6), 1267-1288, 2018
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ...
The Lancet Neurology 20 (7), 526-536, 2021
Review of the diagnosis and treatment of periodic paralysis
JM Statland, B Fontaine, MG Hanna, NE Johnson, JT Kissel, VA Sansone, ...
Muscle & nerve 57 (4), 522-530, 2018
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial
JM Statland, BN Bundy, Y Wang, DR Rayan, JR Trivedi, VA Sansone, ...
Jama 308 (13), 1357-1365, 2012
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ...
Muscle & nerve 60 (1), 14-24, 2019
Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons
JJ Lawrence, F Saraga, JF Churchill, JM Statland, KE Travis, FK Skinner, ...
Journal of Neuroscience 26 (47), 12325-12338, 2006
Primary lateral sclerosis
MA Singer, JM Statland, GI Wolfe, RJ Barohn
Muscle & Nerve: Official Journal of the American Association of …, 2007
Consensus-based care recommendations for adults with myotonic dystrophy type 1
T Ashizawa, C Gagnon, WJ Groh, L Gutmann, NE Johnson, G Meola, ...
Neurology: Clinical Practice 8 (6), 507-520, 2018
Primary lateral sclerosis: consensus diagnostic criteria
MR Turner, RJ Barohn, P Corcia, JK Fink, MB Harms, MC Kiernan, ...
Journal of Neurology, Neurosurgery & Psychiatry 91 (4), 373-377, 2020
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
M Benatar, L Zhang, L Wang, V Granit, J Statland, R Barohn, A Swenson, ...
Neurology 95 (1), e59-e69, 2020
Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis
JM Statland, RJ Barohn, AL McVey, JS Katz, MM Dimachkie
Neurologic clinics 33 (4), 735-748, 2015
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis
M Pasnoor, J He, L Herbelin, TM Burns, S Nations, V Bril, AK Wang, ...
Neurology 87 (1), 57-64, 2016
Targeting protein homeostasis in sporadic inclusion body myositis
M Ahmed, PM Machado, A Miller, C Spicer, L Herbelin, J He, J Noel, ...
Science translational medicine 8 (331), 331ra41-331ra41, 2016
Cell type‐specific dependence of muscarinic signalling in mouse hippocampal stratum oriens interneurones
JJ Lawrence, JM Statland, ZM Grinspan, CJ McBain
The Journal of physiology 570 (3), 595-610, 2006
Facioscapulohumeral muscular dystrophy
JM Statland, R Tawil
CONTINUUM: Lifelong Learning in Neurology 22 (6), 1916-1931, 2016
Non-dystrophic myotonia: prospective study of objective and patient reported outcomes
JR Trivedi, B Bundy, J Statland, M Salajegheh, DR Rayan, SL Venance, ...
Brain 136 (7), 2189-2200, 2013
Facioscapulohumeral muscular dystrophy
J Statland, R Tawil
Neurologic clinics 32 (3), 721-728, 2014
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression
MD Weiss, EA Macklin, Z Simmons, AS Knox, DJ Greenblatt, N Atassi, ...
Neurology 86 (16), 1474-1481, 2016
Primary lateral sclerosis: a heterogeneous disorder composed of different subtypes?
P Zhai, F Pagan, J Statland, JA Butman, MK Floeter
Neurology 60 (8), 1258-1265, 2003
Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials
BC Stunnenberg, J Raaphorst, HM Groenewoud, JM Statland, RC Griggs, ...
Jama 320 (22), 2344-2353, 2018
The system can't perform the operation now. Try again later.
Articles 1–20